Dacogen

DRUG3 trials

Conditions

Acute Myeloid LeukemiaAnogenital CancerChronic Myelomonocytic LeukemiaChronic Myeloproliferative DisordersHead and Neck CancerMyelodysplastic SyndromesSecondary Myelofibrosis

Phase 1

Decitabine Treatment in HPV-Induced Anogenital and Head and Neck Cancer Patients After Radiotherapy or as Novel Late Salvage

TerminatedNCT04252248

University Hospital HeidelbergAnogenital Cancer, Head and Neck Cancer

Start: 2019-10-11End: 2021-06-15Updated: 2021-10-06

Phase 2

Low-Dose Decitabine in Treating Patients With Symptomatic Myelofibrosis

TerminatedNCT00630994

Mayo ClinicChronic Myeloproliferative Disorders, Secondary Myelofibrosis

Start: 2008-03-31End: 2012-04-30Updated: 2015-12-30

Phase 3

Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML

CompletedNCT03306264

Astex Pharmaceuticals, Inc.Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes

Start: 2018-02-15End: 2023-05-25Updated: 2024-08-27

Related Papers

Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study.

2024-01-0157 citations

P735: EFFICACY AND SAFETY OF ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN THE CMML SUBPOPULATION FROM PHASE 2 AND ASCERTAIN PHASE 3 STUDIES

HemaSphere2023-08-012 citations

Recent Advances in the Treatment of Myelodysplastic Syndromes

Oncology Times2020-11-11